16 April 2024
16 April 2024
The investigational drug completed a Phase I clinical trial in healthy volunteers with a good safety profile.
The FDA placed the clinical hold based on the preclinical data that showed that Neumora’s NMRA-266 triggered convulsions in rabbits.
To extend cash reserves, Portage is exploring numerous strategic alternatives including asset sales, mergers, restructuring and company wind-down.
The future development of IV ganaxolone will be determined by results from the Phase III RAISE study, expected in summer 2024.
Soligenix’s Marburg virus vaccine demonstrated 100% protection in non-human primates in a clinical study.
The deal will provide Sanofi with the option to choose services from IDT Australia and allows for additional work packages.
The asset is part of a research collaboration and license agreement with Innate Pharma.
The price ceiling policy has been in place for more than 20 years, but it has neither been very successful nor free of consequences for pharma companies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
